Management of Chronic Hepatitis C Virus Infection: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases

Basit Öğe Kaydı
dc.authoridDemirturk, Nese/0000-0002-6186-2494
dc.authoridSAYAN, MURAT/0000-0002-4374-7193
dc.authoridSaltoglu, Nese/0000-0003-4239-9585
dc.contributor.authorAygen, Bilgehan
dc.contributor.authorKeten, Derya
dc.contributor.authorAkalin, Halis
dc.contributor.authorAsan, Ali
dc.contributor.authorBozdag, Heval
dc.contributor.authorCagir, Unal
dc.contributor.authorDemirturk, Nese
dc.date.accessioned2025-01-27T20:12:14Z
dc.date.available2025-01-27T20:12:14Z
dc.date.issued2014
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractStudy Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases convened a meeting to develop a consensus report on management of chronic hepatitis C virus (HCV) infection, a global public health problem, affecting nearly 170 million people worldwide. Relevant literature and international guidelines were reviewed, and recommendations agreed are presented at the end of each section such as epidemiology and natural history of HCV infection, economic burden of chronic hepatitis C (CHC), diagnosis of acute hepatitis C (AHC) and CHC, treatment of AHC, goals, endpoints, stopping rules and pre-therapeutic assessment of CHC therapy, indications for treatment, treatment of CHC, monitoring and managing treatment safety and side effects, measures to improve treatment adherence, posttreatment follow-up of patients who achieve a sustained virological response, contraindications to therapy, retreatment of non-sustained virological responders, follow-up of untreated patients and of patients with treatment failure, and prevention of HCV infection. Examples of some selected recommendations are as follows: [1] It should be kept in mind that approximately 75-85% of people who become infected will develop chronic HCV infection, up to 20% of them develop cirrhosis within 20 years, and the average annual risk of hepatocellular carcinoma among them is 1-4%. [2] In addition to the HCV RNA quantification, the HCV genotype should be assessed to provide relevant information with respect to treatment duration and different response rates prior to treatment initiation. [3] If predicted response rate is not appropriate to any of the existing regimens, the patient should be kept waited until alternative therapeutic options become available.
dc.identifier.doi10.5152/kd.2014.27
dc.identifier.endpage39
dc.identifier.issn1301-143X
dc.identifier.issn1309-1484
dc.identifier.issue1
dc.identifier.scopus2-s2.0-84925860577
dc.identifier.scopusqualityQ4
dc.identifier.startpage19
dc.identifier.urihttps://doi.org/10.5152/kd.2014.27
dc.identifier.urihttps://hdl.handle.net/20.500.12428/20885
dc.identifier.volume27
dc.identifier.wosWOS:000420946000003
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isotr
dc.publisherAves
dc.relation.ispartofKlimik Journal
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectChronic hepatitis C
dc.subjectantiviral agents
dc.subjecttherapy
dc.titleManagement of Chronic Hepatitis C Virus Infection: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases
dc.title.alternativeKronik Hepatit C Virusu İnfeksiyonunun Yönetimi: Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği Viral Hepatit Çalışma Grubu Uzlaşı Raporu
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu